SHW
62
-6
AIV
64
4
CVS
41
-4
EIX
70
3
THC
60
-5
MSI
72
-3
URI
60
-6
TGT
45
-4
AAP
35
-9
MNST
45
-21
TEL
60
-8
IRM
41
3
DAL
84
-3
ZTS
47
2
MCO
71
-7
CVX
43
-3
JBHT
56
-3
INTU
58
-3
SCHW
62
-2
ED
45
3
SHW
62
-6
AIV
64
4
CVS
41
-4
EIX
70
3
THC
60
-5
MSI
72
-3
URI
60
-6
TGT
45
-4
AAP
35
-9
MNST
45
-21
TEL
60
-8
IRM
41
3
DAL
84
-3
ZTS
47
2
MCO
71
-7
CVX
43
-3
JBHT
56
-3
INTU
58
-3
SCHW
62
-2
ED
45
3
Financhill
Back

RiverNorth/DoubleLine Strategic Opportunity Fund Vs. Halozyme Therapeutics Industry Stock Comparison

Sell
37

OPP
RiverNorth/DoubleLine Strategic Opportunity Fund

Last Price:
8.37
Seasonality Move:
-1.19%
Sell
39

HALO
Halozyme Therapeutics

Last Price:
45.65
Seasonality Move:
17.03%
Sell
37
RiverNorth/DoubleLine Strategic Opportunity Fund (OPP) is a Sell

Is RiverNorth/DoubleLine Strategic Opportunity Fund a Buy, Sell or Hold?

  • The current RiverNorth/DoubleLine Strategic Opportunity Fund [OPP] share price is $8.36. The Score for OPP is 37, which is 26% below its historic median score of 50, and infers higher risk than normal.
  • OPP is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
39
Halozyme Therapeutics (HALO) is a Sell

Is Halozyme Therapeutics a Buy, Sell or Hold?

  • The current Halozyme Therapeutics [HALO] share price is $45.65. The Score for HALO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.
  • HALO is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
  • This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.

OPP Stock Price Chart

What is RiverNorth/DoubleLine Strategic Opportunity Fund's stock price today?

  • The RiverNorth/DoubleLine Strategic Opportunity Fund share price today is $8.36
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and OPP is experiencing selling pressure, which indicates risk of future bearish movement.

HALO Stock Price Chart

What is Halozyme Therapeutics's stock price today?

  • The Halozyme Therapeutics share price today is $45.65
    Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and HALO is experiencing selling pressure, which indicates risk of future bearish movement.

OPP Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.11 Sell
Relative Strength Index (14 RSI): 23.91 Sell
Chaikin Money Flow: -181259 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (8.59 - 8.89) Sell
Bollinger Bands (100): (8.68 - 9.04) Sell

HALO Technical Analysis

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.02 Sell
Relative Strength Index (14 RSI): 30.2 Sell
Chaikin Money Flow: -7140517 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (49.94 - 58.56) Sell
Bollinger Bands (100): (52.16 - 60.38) Sell

OPP Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 8.61 Sell
20-day SMA: 8.68 Sell
50-day SMA: 8.91 Sell
200-day SMA: 8.64 Sell
8-day EMA: 8.56 Sell
20-day EMA: 8.68 Sell
50-day EMA: 8.8 Sell
200-day EMA: 8.7 Sell

HALO Moving Averages

Moving Averages Level Buy or Sell
8-day SMA: 57.53 Sell
20-day SMA: 54.48 Sell
50-day SMA: 56.18 Sell
200-day SMA: 48.93 Sell
8-day EMA: 55 Sell
20-day EMA: 55.41 Sell
50-day EMA: 55.64 Sell
200-day EMA: 50.73 Sell

RiverNorth/DoubleLine Strategic Opportunity Fund Earnings Growth & OPP Earnings Dates

  • Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.

Halozyme Therapeutics Earnings Growth & HALO Earnings Dates

  • Analysts estimate an earnings increase this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.30 per share, and an increase next year of $0.71 per share.

RiverNorth/DoubleLine Strategic Opportunity Fund Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Halozyme Therapeutics Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):